Proteonomix, Inc. (OTCPK:PROT)
PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.
PROT, a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC ("XGen") towards implementing operations in the United Arab Emirates (U.A.E.).
PROT is the majority shareholder in XGen with the balance held by an anonymous investor group. PROT personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting PROT personnel on Jumeira 2.
During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.
To learn more about PROT visit: http://www.proteonomix.com
Evcarco, Inc. (OTC:EVCA)
EVCA is a development stage company and engages in selling environmentally conscious automobiles in the United States. EVCA offers electric vehicles and pre-owned vehicles converted to various green technologies; and financing, warranties, maintenance, and mechanical services. EVCA was incorporated in 2008 and is based in Fort Worth, Texas.
EVCA is pioneering a new way to meet the demands of 21st century car buyers. EVCA is bringing to market eco-friendly vehicles with an emphasis on performance and affordability and the latest in developed technology. The board of EVCA is pleased to announce today that pursuant to a strong demand from the US Federal Government to meet environmental standards in relation to its Federal Military fleet, EVCA will be working with VENTA Inc. and several third party organizations to create Military grade AEV and Hybrid Diesel Electric units.
EVCA has been working on projects with the US Federal Government as announced in previous releases since first quarter of 2010; the trials have given the management of EVCA insight into the needs and requirements of the Federal Government and, with this knowledge, the corporation stands at a significant advantage in respect to sourcing specific AEV and Hybrid Units for the Military.
The US Military through TARDEC has set a strong precedent relating to adoption of Alternative energy units into the US Military. TARDEC is the U.S. Army's lead organization for ground vehicle systems integration, engineering and technology development.
Initial development of units will be entered into testing phase by late 2010 with "Real World" Government testing anticipated for early 2011.
AFVs are vehicles that operate on alternative fuels, such as methanol, ethanol, compressed natural gas, liquefied petroleum gas, or electricity, as designated by the U.S. Department of Energy. Some AFVs that can run on conventional fuels like gasoline, as well as alternative fuels, are called dual-fueled vehicles.
To learn more about EVCA visit: http://www.evcarco.com
PolyOne Corporation (NYSE:POL)
POL recently announced the pricing of $360 million of senior notes in an underwritten public offering. The offering consists of $360 million aggregate principal amount of 7.375% senior notes issued at par due September 2020. Interest on the notes will be paid semi-annually on March 15 and September 15. The offering is expected to close on or about September 24, 2010, subject to customary closing conditions.
POL provides specialized polymer materials, services, and solutions with operations in thermoplastic compounds, specialty polymer formulations, color and additive systems, thermoplastic resin distribution, and specialty polyvinyl chloride (PVC) resins. POL was founded in 1927 and is headquartered in Avon Lake, Ohio.
To learn more about POL visit: http://www.polyone.com
Polypore International, Inc. (NYSE:PPO)
PPO recently reported its financial results for the second quarter ended July 3, 2010.
- Sales were $150.1 million, an increase of $31.9 million, or 27%, compared with the prior-year period. Excluding the effect of foreign currency translation, sales increased 29%.
- Adjusted Operating Income was $32.7 million compared with $23.0 million in the prior-year period. A table showing the reconciliation of Adjusted Operating Income to U.S. GAAP amounts is included in this release.
- Adjusted Net Income and Adjusted EPS were $15.2 million and $0.33 per diluted share, compared with $5.2 million and $0.12 per diluted share in the prior-year period. Net income was $15.9 million and $0.34 per diluted share. A table showing the reconciliation of Adjusted Net Income and Adjusted EPS to U.S. GAAP amounts is included in this release.
PPO, a technology filtration company, develops, manufactures, and markets microporous membranes used in separation and filtration processes. PPO operates in two segments, Energy Storage and Separations Media. PPO is headquartered in Charlotte, North Carolina.
To learn more about PPO visit: http://www.polypore.net
Poniard Pharmaceuticals, Inc. (Nasdaq:PARD)
PARD, a biopharmaceutical company focused on innovative oncology therapies, recently reported financial results for the second quarter ended June 30, 2010.
PARD reported a net loss of $6.5 million ($0.14 diluted loss per share on a loss applicable to common shares of $6.6 million) for the quarter ended June 30, 2010. As of June 30, 2010, cash and investment securities totaled $29.3 million. Management currently believes that existing cash and investment securities will provide adequate resources to fund PARD's operations at least through the end of 2010.
PARD, together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of cancer therapeutics. PARD was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006. PARD was founded in 1984 and is headquartered in South San Francisco, California.
To learn more about PARD visit: http://www.poniard.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT) Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received fifteen thousand dollars in cash and thirty-five thousand dollars in EVCARCO, Inc. (OTC:EVCA) restricted shares for 30 days of advertising.